Deutsche Märkte geschlossen

Boston Scientific Corporation (BSX)

NYSE - NYSE Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
73,17-0,09 (-0,12%)
Börsenschluss: 04:00PM EDT
72,50 -0,67 (-0,92%)
Nachbörse: 07:51PM EDT

Boston Scientific Corporation

300 Boston Scientific Way
Marlborough, MA 01752-1234
United States
508 683 4000
https://www.bostonscientific.com

Sektor(en)Healthcare
BrancheMedical Devices
Vollzeitmitarbeiter48.000

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Michael F. MahoneyChairman, President & CEO4,83M12,98M1965
Mr. Daniel J. BrennanExecutive VP & CFO2,15M1,71M1966
Mr. Joseph M. FitzgeraldExecutive VP & Group President of Cardiology1,84M4,7M1964
Mr. Jeffrey B. MirvissExecutive VP & President of Peripheral Interventions1,44MN/A1966
Mr. Arthur Crosswell ButcherExecutive VP and Group President of MedSurg & Asia Pacific1,49M626,04k1971
Mr. David J. RouxIndependent Director135kN/A1957
Mr. John Bradley SorensonExecutive Vice President of Global OperationsN/AN/A1968
Ms. Emily WoodworthSenior VP, Global Controller & Chief Accounting OfficerN/AN/A1978
Ms. Jodi Euerle EddySenior VP and Chief Information & Digital OfficerN/AN/A1974
Mr. Jonathan R MonsonSenior VP of Investor RelationsN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

Boston Scientific Corporations ISS Governance QualityScore, Stand 1. April 2024, lautet 9. Die grundlegenden Scores sind Audit: 10, Vorstand: 9, Shareholderrechte: 8, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.